for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Teva Pharmaceutical Industries Limited

TEVA.TA

Latest Trade

3,195.00ILa

Change

-70.00(-2.14%)

Volume

809,294

Today's Range

3,185.00

 - 

3,284.00

52 Week Range

2,430.00

 - 

4,709.00

As of on the Tel Aviv Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3,265.00
Open
3,280.00
Volume
809,294
3M AVG Volume
24.26
Today's High
3,284.00
Today's Low
3,185.00
52 Week High
4,709.00
52 Week Low
2,430.00
Shares Out (MIL)
1,095.97
Market Cap (MIL)
35,626.26
Forward P/E
3.89
Dividend (Yield %)
--

Next Event

Q4 2020 Teva Pharmaceutical Industries Ltd Earnings Release

Latest Developments

More

Teva Pharmaceutical Industries Q3 GAAP Loss Per Share $3.97

Collegium Announces Settlement With Teva Resolving Xtampza Er Patent Litigation

Alkermes Files Lawsuit Against Teva USA & Teva Pharmaceutical Industries

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Industry

Biotechnology & Drugs

Contact Info

5 Bazel St, P O B 3190

49131

Israel

+972.3.9267267

http://www.tevapharm.com

Executive Leadership

Sol J. Barer

Independent Chairman of the Board

Kaare Schultz

President, Chief Executive Officer, Director

Eliyahu Sharon Kalif

Chief Financial Officer, Executive Vice President

Mark Sabag

Executive Vice President, Chief Human Resources Officer and Global Communications and Brand

Richard Daniell

Executive Vice President - European Commercial

Key Stats

2.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.4K

2018

18.9K

2020(E)

16.5K
EPS (USD)

2017

4.010

2019

-0.910

2020(E)

2.520
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.66
Price To Book (MRQ)
1.11
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
267.08
LT Debt To Equity (MRQ)
245.13
Return on Investment (TTM)
-10.98
Return on Equity (TTM)
-8.07

Latest News

Latest News

UPDATE 1-Teva in EU antitrust crosshairs over its Copaxone drug

Israeli drugmaker Teva is the target of an EU antitrust investigation over the possible abuse of its dominant position related to its multiple sclerosis medicine Copaxone, the European Commission said on Friday.

EU antitrust regulators investigating Teva over its Copaxone drug

EU antitrust regulators are investigating Israeli drugmaker Teva over the possible abuse of its dominant position related to its multiple sclerosis medicine Copaxone, the European Commission said on Friday.

UPDATE 2-Teva Pharm Q3 profit in line with forecasts, lowers 2020 rev outlook

Israel-based Teva Pharmaceutical Industries reported quarterly profit in line with expectations but lowered its 2020 revenue forecast on lower demand for some products as fewer people are going to hospitals and doctors during the pandemic.

Japan's Sosei allies with ex-Novartis team to develop neurological drug pipeline

Japan's Sosei Group Corp said on Monday it is allying with a U.S. biotech run by former Novartis AG executives to commercialise a neurological drug pipeline.

BRIEF-U.S. Settles With Oxycontin Drugmaker Purdue Pharma Over Opioids -Document

* U.S. SETTLES WITH OXYCONTIN DRUGMAKER PURDUE PHARMA OVER OPIOIDS -DOCUMENT Source text for Eikon: Further company coverage:

U.S. appeals court revives Glaxo $235.5 million verdict against Teva

A federal appeals court on Friday reinstated a 2017 jury verdict ordering Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc $235.5 million for selling a generic version of Glaxo's heart drug Coreg.

BRIEF-Teva plans to appeal verdict favoring Glaxo concerning Coreg drug

Teva says it plans to appeal u.s. Court's reinstatement of jury verdict favoring glaxosmithkline, and plans to present additional defenses related to the drug coreg

U.S. appeals court revives GlaxoSmithKline verdict against Teva

A federal appeals court on Friday reinstated a 2017 jury verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent for its blood pressure drug Coreg.

New York charges Johnson & Johnson with insurance fraud over opioid claims

New York state filed civil charges on Thursday accusing Johnson & Johnson of insurance fraud for downplaying the risks of opioid painkillers, including to elderly patients.

U.S. charges Teva in generic drugs price-fixing probe

The U.S. Justice Department charged Teva Pharmaceutical Industries Ltd on Tuesday with conspiring with competitors to raise prices for generic drugs.

U.S. charges founder of drug company bought by Teva in insider trading case

U.S. prosecutors brought insider trading charges against the founder and former chief executive of Auspex Pharmaceuticals Inc, accusing him of providing illegal tips to friends and family as Teva Pharmaceutical Industries Ltd <TEVA.TA> prepared to buy his company in a $3.5...

US charges ex-CEO of drug company with fraud tied to Teva tender offer

U.S. prosecutors on Tuesday announced insider trading charges accusing the former chief executive of Auspex Pharmaceuticals Inc with tipping friends and family about an anticipated tender offer for his company by Teva Pharmaceutical Industries Ltd in 2015.

U.S. to charge Teva in generic drugs price-fixing probe: Bloomberg Law

U.S. Justice Department is preparing to charge Teva Pharmaceutical Industries Ltd with conspiring with competitors to raise prices for generic drugs, Bloomberg Law reported on Tuesday citing a person familiar with the matter.

New York charges Teva, Allergan with insurance fraud over opioid claims

New York state filed civil charges on Tuesday accusing Teva Pharmaceutical Industries Ltd and Allergan Plc with insurance fraud for downplaying the risks of their opioid painkillers to patients and doctors.

New York files insurance fraud charges against opioid makers Teva, Allergan

New York Governor Andrew Cuomo said on Tuesday the State Department of Financial Services had filed charges against Teva Pharmaceuticals and Allergan Plc over their role in the opioid crisis.

U.S. sues Teva over alleged kickbacks for multiple sclerosis drug

The U.S. government sued Teva Pharmaceutical Industries Ltd <TEVA.TA> on Tuesday, accusing the drugmaker of causing the submission of false claims to Medicare by using kickbacks to boost sales of its multiple sclerosis drug Copaxone.

U.S. sues Teva over alleged kickbacks for multiple sclerosis drug

REUTERS - The U.S. government sued Teva Pharmaceutical Industries Ltd on Tuesday, accusing the drugmaker of causing the submission of false claims to Medicare as a result of kickbacks it paid for its multiple sclerosis drug Copaxone.

Pharmacy to pay $3.5 million to resolve U.S. claims it helped Teva pay kickbacks

A Florida-based specialty pharmacy will pay $3.5 million to resolve allegations it served as a conduit for a Teva Pharmaceutical Industries Ltd subsidiary to pay kickbacks to Medicare patients, the U.S. Justice Department said on Thursday.

Teva Pharm second-quarter profit tops forecast, reaffirms 2020 outlook

Teva Pharmaceutical Industries' <TEVA.TA> quarterly profit beat estimates by two cents and the company reaffirmed its outlook for 2020 despite uncertainty generated by the COVID-19 crisis.

BRIEF-Teva Presents New Analyses Examining Changes In Migraine Disability Outcome Measurements With Ajovy Injection

* TEVA PRESENTS NEW ANALYSES EXAMINING CHANGES IN MIGRAINE DISABILITY OUTCOME MEASUREMENTS WITH AJOVY® (FREMANEZUMAB-VFRM) INJECTION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up